113 related articles for article (PubMed ID: 10099929)
21. Coronary events with lipid-lowering therapy: the AFCAPS/TexCAPS trial. Air Force/Texas Coronary Atherosclerosis Prevention Study.
Siegel D; Swislocki AL
JAMA; 1999 Feb; 281(5):417-9. PubMed ID: 9952198
[No Abstract] [Full Text] [Related]
22. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease.
Martens LL; Guibert R
Clin Ther; 1994; 16(6):1052-62; discussion 1036. PubMed ID: 7697684
[TBL] [Abstract][Full Text] [Related]
23. Coronary events with lipid-lowering therapy: the AFCAPS/TexCAPS trial. Air Force/Texas Coronary Atherosclerosis Prevention Study.
Mason JM; Freemantle N
JAMA; 1999 Feb; 281(5):415-6; author reply 417-9. PubMed ID: 9952194
[No Abstract] [Full Text] [Related]
24. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels.
Tsevat J; Kuntz KM; Orav EJ; Weinstein MC; Sacks FM; Goldman L
Am Heart J; 2001 May; 141(5):727-34. PubMed ID: 11320359
[TBL] [Abstract][Full Text] [Related]
25. [Use of statins in primary prevention: from the theoretical presuppositions to complex scenarios of the real world].
Poli A; Menotti A
G Ital Cardiol; 1999 Oct; 29(10):1123-30. PubMed ID: 10546121
[No Abstract] [Full Text] [Related]
26. Statins and coronary heart disease.
Thompson GR
Lancet; 1996 Jul; 348(9019):57. PubMed ID: 8691944
[No Abstract] [Full Text] [Related]
27. [Coronary disease prevention: only the inhibition of inflammation is important. Why lower lipids, too?].
Sudhop T; von Bergmann K
MMW Fortschr Med; 2003 May; 145(21):19. PubMed ID: 12845862
[No Abstract] [Full Text] [Related]
28. Economic benefit analysis of primary prevention with pravastatin. Modelling economic benefits after such long term treatment is inappropriate.
Pharoah P
BMJ; 1998 Apr; 316(7139):1241-2. PubMed ID: 9553009
[No Abstract] [Full Text] [Related]
29. [Simvastatin 40 mg as secondary prophylaxis: Effective, tolerable and cost-efficient!].
Hernborg A; Hjemdahl P; Håkansson J
Lakartidningen; 2006 Mar 15-21; 103(11):858, 861; discussion 861-2. PubMed ID: 16613120
[No Abstract] [Full Text] [Related]
30. Cost-effectiveness of cholesterol-lowering therapy with pravastatin in patients with previous acute coronary syndromes aged 65 to 74 years compared with younger patients: results from the LIPID study.
Tonkin AM; Eckermann S; White H; Friedlander D; Glasziou P; Magnus P; Kirby A; Mulray S; Denton M; Sallaberger M; Hunt D; Simes J;
Am Heart J; 2006 Jun; 151(6):1305-12. PubMed ID: 16781242
[TBL] [Abstract][Full Text] [Related]
31. [Socioeconomic aspects of therapy of cardiovascular diseases].
Lauterbach KW
Herz; 2000 Aug; 25(5):473-5. PubMed ID: 10992995
[No Abstract] [Full Text] [Related]
32. Pravastatin for Primary Prevention in Older Adults: Restricted Mean Survival Time Analysis.
Orkaby AR; Rich MW; Sun R; Lux E; Wei LJ; Kim DH
J Am Geriatr Soc; 2018 Oct; 66(10):1987-1991. PubMed ID: 30251369
[TBL] [Abstract][Full Text] [Related]
33. [Pharmaco-economic aspects of hypolipidemic treatment].
Scheen AJ
Rev Med Liege; 1997; 52(1):16-21. PubMed ID: 9064710
[No Abstract] [Full Text] [Related]
34. [Statin treatment in type 2 diabetes. Is it a must today?].
Faust M
MMW Fortschr Med; 2003 Feb; 145(9):35-6. PubMed ID: 12666527
[No Abstract] [Full Text] [Related]
35. [Can the action of statins reveal etiology of coronary diseases?].
Werkö L
Lakartidningen; 2001 Oct; 98(42):4566-7. PubMed ID: 11715228
[No Abstract] [Full Text] [Related]
36. Primary prevention of coronary artery disease.
Domanski MJ
N Engl J Med; 2007 Oct; 357(15):1543-5. PubMed ID: 17928603
[No Abstract] [Full Text] [Related]
37. The effect of low-dose pravastatin in metabolic syndrome for primary prevention of cardiovascular disease in Japan: a post hoc analysis of the MEGA study.
Matsushima T; Nakaya N; Mizuno K; Ohashi Y; Teramoto T; Yokoyama S; Ichikawa S; Ishikura N; Kamiyama K; Nakamura H;
J Cardiovasc Pharmacol Ther; 2012 Jun; 17(2):153-8. PubMed ID: 22573644
[TBL] [Abstract][Full Text] [Related]
38. Screening for cholesterol?
Kerrigan P
Practitioner; 1989 May; 233(1468):627. PubMed ID: 2513564
[No Abstract] [Full Text] [Related]
39. [The new debate on cholesterol: is the lowest level the best?].
Olsson AG
Lakartidningen; 1999 Feb; 96(6):648-52. PubMed ID: 10087815
[No Abstract] [Full Text] [Related]
40. Cost-effectiveness analyses.
Clark CM
Ann Intern Med; 2001 Sep; 135(5):382-3. PubMed ID: 11529708
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
